Condition: Solid Tumors · Sponsor: Shionogi
The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab. The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D with or without pembrolizumab. The primary objective of Parts D and E is to evaluate the antitumor activity of S-531011 at the RP2D in combination with bevacizumab with our without pembrolizumab.
This description comes directly from the study's public registry record.
Shionogi Clinical Trials Administrator Clinical Support Help Line · 800-849-9707 · Shionogiclintrials-admin@shionogi.co.jp
Always discuss trial participation with your own doctor first.
| Angeles Clinic and Research Center | Los Angeles, California, United States | Active Not Recruiting |
| University of Florida Health | Gainesville, Florida, United States | Recruiting |
| Henry Ford Health Center | Detroit, Michigan, United States | Active Not Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| National Cancer Center Hospital East | Kashiwa, Chiba, Japan | Recruiting |
| The University of Osaka Hospital | Suita, Osaka, Japan | Recruiting |
| National Cancer Center Hospital | Chuo Ku, Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05101070